Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

NCT07102901 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

351

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Gastric Cancer
Metastatic Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: SHR2554 Tablets
DRUG: SHR-A1811 Injection
DRUG: SHR-A1904 Injection
DRUG: SHR-1701 Injection

Sponsor

Jiangsu HengRui Medicine Co., Ltd.